Published On: Wed, Oct 19th, 2016

Analyst Review: Halozyme Therapeutics, Inc. (NASDAQ:HALO)


A number of investment brokers have recently updated their price targets on shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO).

Most recent broker ratings

09/16/2016 – Halozyme Therapeutics, Inc. had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 18 price target on the stock.

02/24/2016 – Halozyme Therapeutics, Inc. had its “overweight” rating reiterated by analysts at Barclays. They now have a USD 16 price target on the stock.

02/01/2016 – Canaccord Genuity began new coverage on Halozyme Therapeutics, Inc. giving the company a “buy” rating. They now have a USD 10 price target on the stock.

01/20/2016 – Halozyme Therapeutics, Inc. had its “buy” rating reiterated by analysts at UBS. They now have a USD 22 price target on the stock.

12/03/2015 – Wells Fargo began new coverage on Halozyme Therapeutics, Inc. giving the company a “outperform” rating.

11/18/2015 – Citigroup began new coverage on Halozyme Therapeutics, Inc. giving the company a “buy” rating. They now have a USD 25 price target on the stock.

08/11/2015 – Halozyme Therapeutics, Inc. had its “buy” rating reiterated by analysts at JMP Securities. They now have a USD 22 price target on the stock.

06/22/2015 – Halozyme Therapeutics, Inc. had its “overweight” rating reiterated by analysts at JP Morgan. They now have a USD 25 price target on the stock.

06/01/2015 – Halozyme Therapeutics, Inc. had its “buy” rating reiterated by analysts at MLV & Co. They now have a USD 20 price target on the stock.

04/20/2015 – Halozyme Therapeutics, Inc. had its “outperform” rating reiterated by analysts at BMO Capital Markets. They now have a USD 26 price target on the stock.

11/12/2014 – Halozyme Therapeutics, Inc. had its “outperform” rating reiterated by analysts at William Blair.

10/14/2014 – Halozyme Therapeutics, Inc. was upgraded to “outperform” by analysts at Zacks. They now have a USD 10.4 price target on the stock.

09/15/2014 – Halozyme Therapeutics, Inc. had its “underperform” rating reiterated by analysts at Jefferies. They now have a USD 5 price target on the stock.

04/15/2014 – Halozyme Therapeutics, Inc. had its “buy” rating reiterated by analysts at Citic Securities. They now have a USD 12 price target on the stock.

The share price of Halozyme Therapeutics, Inc. (NASDAQ:HALO) was down -0.10% during the last day of trading, with a day high of 10.01. 1043395 shares were traded during the last session.

The stock’s 50 day moving average is 11.27 and its 200 day moving average is 10.15. The stock’s market capitalization is 1.24B. Halozyme Therapeutics, Inc. has a 52-week low of 6.96 and a 52-week high of 18.65.

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant. Its development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).